File:PMC4882345 280 2016 3012 Fig1 HTML.png

License

Attribution 4.0 International (CC BY 4.0)

Summary

Author:Bryan JC, Verstovsek S,Pharmacy Clinical Programs, Division of Pharmacy, The University of Texas MD Anderson Cancer Center(Openi/National Library of Medicine) Source:https://openi.nlm.nih.gov/detailedresult?img=PMC4882345_280_2016_3012_Fig1_HTML&query=Polycythemia%20vera&it=xg&req=4&npos=82 Description:Fig1: a Mutations underlying the pathobiology of myelofibrosis. Mutations commonly affect the JAK–STAT pathway, including those that occur directly in JAK2 such as the JAK2V617F mutation, or indirectly such as those in MPL, which encodes the thrombopoietin receptor, or in CALR, which may activate STATs through an unknown mechanism. Somatic mutations in epigenetic modifiers can also result in increased myeloproliferation, survival, and cytokine expression in myelofibrosis. From [12]. Copyright © 2014. b The approximate proportion of patients with JAK2, MPL, and CALR mutations was examined in 203 patients with primary myelofibrosis. From [10].Copyright © 2013 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. CALR calreticulin, JAK Janus kinase, MPL myeloproliferative leukemia virus oncogene, STAT signal transducer and activator of transcription